KIORA PHARMACEUTICALS INC
KPRX$8M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaENCINITAS12 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 15, 2026
36wMarket Overview
Stock performance and key metrics
KPRX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
KIO-104
Macular Edema
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
Persistent Corneal Epithelial Defect
KIO-301
Retinitis Pigmentosa
100 μg KIO-301
Retinitis Pigmentosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KIO-104 | Phase 2 | Macular Edema | - | - |
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Phase 2 | Persistent Corneal Epithelial Defect | - | - |
KIO-301 | Phase 2 | Retinitis Pigmentosa | - | - |
100 μg KIO-301 | Phase 2 | Retinitis Pigmentosa | - | - |
Retinitis Pigmentosa
2 drugs in this indication
Macular Edema
1 drug in this indication
Persistent Corneal Epithelial Defect
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply